Research programme: pure estrogen receptor antagonists - ProStrakanAlternative Names: PSK-3668
Latest Information Update: 19 Sep 2007
At a glance
- Originator ProStrakan
- Class Antineoplastics
- Mechanism of Action Estrogen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Sep 2007 Discontinued - Preclinical for Cancer in Europe (unspecified route)
- 19 Apr 2006 This programme is still in active development
- 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan